Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 3/20 | 0.43 |
| ▸ | AXL | P30530 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969043 | 0.91 | HTR3A (0.44) | HTR3AMETAXLATMMAPK14 | |
| SCHEMBL30031006 | 0.90 | PARP1 (0.44) | HTR3AMETAXLATMMAPK14 | |
| SCHEMBL14967149 | 0.85 | CNR1 (0.45) | HTR3AMETAXLATMCNR2 | |
| SCHEMBL23749476 | 0.82 | MET (0.47) | METAXL | |
| SCHEMBL23771043 | 0.80 | MET (0.39) | METAXLKDM4ELMNA | |
| SCHEMBL23749310 | 0.80 | AXL (0.41) | METAXL | |
| SCHEMBL22511523 | 0.76 | AXL (0.52) | METAXLCNR2CNR1 | |
| SCHEMBL23749414 | 0.76 | MET (0.46) | METAXL | |
| SCHEMBL14966703 | 0.76 | MET (0.48) | HTR3AMETCNR2CNR1KDM4E | |
| SCHEMBL23749366 | 0.76 | MET (0.49) | METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| CN-111196814-B | Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-111196814-A | Aromatic ring connecting dioxane quinazoline or quinoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2020-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | HTR3A 598/4885MET 14/4885AXL 2/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | HTR3A 748/4885MET 12/4885AXL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.